This move is archived. Current quotes and coverage live on the stock page.
Follow EPRX
Eupraxia Pharmaceuticals Inc faces a notable decline as it slips 3.47% in today's trading session.
Eupraxia Pharmaceuticals Inc (EPRX.TO) closed at CA$9.46 after a 3.47% drop in the last trading session. This decline raises concerns among investors about the company's recent financial moves and overall market sentiment.
Investor takeaway: Investors should keep a close eye on Eupraxia's financial health and market reactions, especially after its recent public offerings aimed at funding clinical trials.
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
WealthAwesomeMarket cap
$626.38M
52W high
$13.08
52W low
$7.70
1W change
-7.78%
Beta
1.33
Analyst Price Targets
Based on analyst covering EPRX · as of Sep 28, 2026
Wall Street analysts forecast EPRX stock price to rise 147.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$16.33
+147.5% Upside
Previously C$16.00 on Sep 17, 2026
Current Price
C$6.60
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
86.2%
Annualized
90-Day Vol
74.4%
Annualized
Trend (90d)
-5.4%
Annualized drift
90d Mean
C$9.05
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.17 | C$6.81 – C$12.35 |
| 60 trading days | C$9.11 | C$5.98 – C$13.88 |
| 90 trading days | C$9.05 | C$5.41 – C$15.16 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Eupraxia Pharmaceuticals Inc down 3.47% today
The company's market cap is about CA$618 million, reflecting investor caution amid recent funding activities.
Bull case
Eupraxia's recent public offerings have strengthened its balance sheet. If the clinical trials yield positive results, the company could be well-positioned for future growth.
Bear case
The stock's decline today may signal investor skepticism about Eupraxia's ability to turn its financing into successful clinical outcomes or profitability.
Market Reaction to Recent Offerings
Eupraxia's recent public offerings, which aimed to raise significant funds for clinical trials, have not generated much enthusiasm in the market. The company announced a public offering of common shares priced at US$7.00, raising concerns about dilution and whether these funds will effectively support long-term growth. Investors are cautious, as today's stock performance reflects uncertainty about the company's future prospects.
Investor Sentiment and Future Outlook
The drop in Eupraxia's stock price today may reflect broader skepticism among investors regarding the company's ability to convert its recent capital raises into successful clinical outcomes. With the market cap hovering around CA$618 million, investors will be closely watching the company's next steps, particularly the results from ongoing clinical trials of its lead program, EP-104GI. The key question is whether these recent financing efforts will lead to tangible progress.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
